PRNewswire - Beckman Coulter Diagnostics announces FDA clearance and U.S. commercial launch of its new DxC 700 AU chemistry analyzer. The new system brings together the advanced capabilities of two successful Beckman Coulter products – the simple intuitive design of the DxC analyzer and the robust throughput and workhorse capabilities of the AU analyzer – into one standardized platform designed to meet the needs of mid- to high-volume clinical laboratories.
"In today's changing healthcare climate, laboratories are asked to elevate care and to reduce costs," said John Blackwood, senior vice president of chemistry and immunoassay at Beckman Coulter Diagnostics. "With the DxC 700 AU analyzer, Beckman Coulter Diagnostics has created a truly innovative product by combining two time-proven technologies of DxC and AU. Additionally, by gaining further input from the clinical laboratory professionals, who are under pressure daily to produce faster results and manage resources more efficiently, additional features and benefits were identified and designed into the product". The DxC 700 AU chemistry analyzer reduces the number of test-processing steps by 30%... >>>